natgillin/translations-raw huggingface dataset:
The main measures of effectiveness were average daily weight gain in the finishing period (fattening pigs in the period prior to slaughter) and PCV2 viraemia (virus in the blood). 
Glavni merili učinkovitosti sta bili povprečni dnevni prirastek telesne mase med zaključnim obdobjem (pitanjem prašičev v obdobju pred zakolom) in viremija virusa PCV2 (prisotnost virusa v krvi).
The most common side effect with Porcilis PCV ID (seen in more than 1 in 10 pigs) is a short-lived local reaction with hard non-painful swellings up to 2 cm in diameter which disappear within about five weeks of vaccination. 
Najpogostejši neželeni učinek cepiva Porcilis PCV ID (opažen pri več kot 1 prašiču od 10) je kratkotrajna lokalna reakcija s trdimi nebolečimi oteklinami premera do 2 cm, ki izginejo v petih tednih po cepljenju.
PCV2 is recognised as the primary cause of post-weaning multisystemic wasting syndrome (PMWS), but is also associated with a number of other conditions collectively known as porcine circovirus disease in Europe (PCVD) e.g porcine respiratory disease complex (PRDC), enteritis, reproductive disorders. 
PCV2 je znan kot primarni povzročitelj sindroma poodstavitvenega hiranja (PMWS), povezujemo pa ga tudi s številnimi drugimi boleznimi, ki jih v Evropi poznamo pod skupnim imenom prašičje cirkovirusne bolezni (PCVD), ki med drugim vključujejo prašičji respiratorni bolezenski kompleks (PRDC), enteritis in reproduktivne motnje.
The withdrawal period for meat from pigs treated with Porcilis PCV ID is ‘zero' days, which means that there is no mandatory waiting time. 
Karenca za meso prašičev, zdravljenih s cepivom Porcilis PCV ID, je nič dni, kar pomeni, da ni obvezne čakalne dobe.
The vaccine is used to reduce viraemia (presence of the virus in the blood), virus load in the lungs and lymphoid tissues and virus shedding. 
Cepivo se uporablja za zmanjšanje viremije (prisotnosti virusa v krvi), virusnega bremena v pljučih in limfnih tkivih ter izločanja virusa.
Porcilis PCV ID has also been investigated in three field studies involving pig farms where PCV2 infection was present. 
Zdravilo Porcilis PCV ID so raziskali tudi v treh terenskih študijah na prašičjih farmah, na katerih je bila prisotna okužba s PCV2.
In all three studies average daily weight gain in the finishing period was significantly higher in the pigs vaccinated with Porcilis PCV ID compared with the non-vaccinated pigs. 
V vseh treh študijah je bil povprečni dnevni prirastek telesne mase med zaključnim obdobjem pri prašičih, cepljenih s cepivom Porcilis PCV ID, znatno večji kot pri necepljenih prašičih.
Porcilis PCV ID is an emulsion containing mineral oil. 
Zdravilo Porcilis PCV ID je emulzija, ki vsebuje mineralno olje.
Similarly PCV2 viraemia was significantly lower in the vaccinated pigs compared with non-vaccinated pigs. 
Podobno je bila tudi viremija virusa PCV2 pri cepljenih prašičkih znatno manjša kot pri necepljenih.
Porcilis PCV ID is available as an emulsion for injection and can only be obtained with a prescription. 
Zdravilo Porcilis PCV ID je na voljo v obliki emulzije za injiciranje in se izdaja le na recept.
Porcilis PCV ID is a vaccine. 
Zdravilo Porcilis PCV ID je cepivo.
Porcilis PCV ID contains the adjuvant light mineral oil and dl-α-tocopheryl acetate to enhance the immune response. 
Zdravilo Porcilis PCV ID vsebuje tudi dodatka, lahko mineralno olje in dl-α-tokoferil acetat, ki povečata imunski odziv.
PCVDs are considered to have a severe impact on pig production. 
Prašičje cirkovirusne bolezni imajo velik vpliv na prašičerejo.
The vaccine is also used to reduce loss of daily weight gain and mortality associated with PV2 infection. 
Prav tako se uporablja za zmanjšanje izgube dnevnega prirasta telesne mase in umrljivosti, povezanih s to okužbo.
Porcilis PCV ID is a veterinary vaccine against porcine circovirus type 2 (PCV2) infection in pigs. 
Zdravilo Porcilis PCV ID je cepivo za uporabo v veterinarski medicini proti okužbi s prašičjim cirkovirusom tipa 2 (PCV2) pri prašičih.
What are the risks associated with Porcilis PCV ID? 
Kakšna tveganja so povezana z zdravilom Porcilis PCV ID?
What is Porcilis PCV ID and what is it used for? 
Kaj je zdravilo Porcilis PCV ID in za kaj se uporablja?
For practical information about using Porcilis PCV ID, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist. 
Za praktične informacije o uporabi zdravila Porcilis PCV ID naj lastniki ali skrbniki živali preberejo navodilo za uporabo ali se posvetujejo z veterinarjem ali farmacevtom.
For more information about treatment with Porcilis PCV ID, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist. 
Za več informacij o zdravljenju z zdravilom Porcilis PCV ID naj lastniki ali skrbniki živali preberejo navodilo za uporabo ali se posvetujejo z veterinarjem ali farmacevtom.
What benefits of Porcilis PCV ID have been shown in studies? 
Kakšne koristi je zdravilo Porcilis PCV ID izkazalo v študijah?
Other information about Porcilis PCV ID 
Druge informacije o zdravilu Porcilis PCV ID
Safety information has been included in the summary of product characteristics and the package leaflet for Porcilis PCV ID, including the appropriate precautions to be followed by healthcare professionals and animal owners or keepers. 
V povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo so bile vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in lastniki ali skrbniki živali.
This will help reduce the PCV2 viraemia, virus load in the lungs and lymphoid tissue and virus shedding. 
To pomaga zmanjšati viremijo, virusno breme v pljučih in limfnih tkivih ter izločanje virusa pri okužbi s PCV2.
Porcilis PCV ID contains the active substance porcine circovirus (PCV2) ORF2 subunit antigen. 
Zdravilo Porcilis PCV ID vsebuje zdravilno učinkovino antigensko podenoto ORF2 prašičjega cirkovirusa (PCV2).
PCV2 infection is widespread and nearly all pig herds are infected with PCV2. 
Okužba s prašičjim cirkovirusom tipa 2 je zelo pogosta, tako da so s tem okužene skoraj vse črede prašičev.
It will also help to reduce the loss of daily weight gain and mortality associated with PCV2 infection. 
Prav tako se uporablja za zmanjšanje izgube dnevnega prirasta telesne mase in umrljivosti, povezanih z okužbo s prašičjim cirkovirusom tipa 2 (PCV2).
How does Porcilis PCV ID work? 
Kako zdravilo Porcilis PCV ID deluje?
The vaccine is given to fattening pigs from three weeks of age as a single injection into the skin at the side of the neck, along the back or in the hind leg. Protection against PCV 2 starts two weeks after vaccination and lasts for 23 weeks after vaccination. 
Zaščita pred virusom PCV2 se razvije dva tedna po cepljenju in traja 23 tednov po njem.
It is not intended to provide practical advice on how to use Porcilis PCV ID. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
How is Porcilis PCV ID used? 
Za kaj se zdravilo Porcilis PCV ID uporablja?
See section 2, Do not take Efficib. 
Glejte poglavje 2, Ne jemljite zdravila Efficib.
If you stop taking Efficib, your blood sugar may rise again. 
Če prenehate jemati zdravilo Efficib, se vam krvni sladkor lahko ponovno poviša.
Efficib is contraindicated in patients with: 
Zdravilo Efficib je kontraindicirano pri:
If no adequate strength of Efficib is available, individual monocomponents should be used instead of the fixed-dose combination. 
Če ni na voljo ustrezne jakosti zdravila Efficib, je treba namesto fiksne kombinacije uporabiti posamične monokomponente.
The safety and efficacy of Efficib in children and adolescents from birth to < 18 years of age have not been established. 
Varnost in učinkovitost zdravila Efficib pri otrocih in mladostnikih, od rojstva do starosti < 18 let, nista bili dokazani.
What Efficib is and what it is used for 
Kaj je zdravilo Efficib in za kaj ga uporabljamo
Efficib must be discontinued at the time of surgery under general, spinal or epidural anaesthesia. 
Uporabo zdravila Efficib je treba v času kirurškega posega pod splošno, spinalno ali epiduralno anestezijo prekiniti.
Your doctor may ask you to stop Efficib. 
Zdravnik vam bo morda naročil, da prenehate z jemanjem zdravila Efficib.
What you need to know before you take Efficib 
Kaj morate vedeti, preden boste vzeli zdravilo Efficib
STOP taking Efficib and contact a doctor immediately if you notice any of the following serious side effects: 
Zdravilo Efficib takoj PRENEHAJTE jemati in se posvetujte z zdravnikom, če opazite katerega koli od naslednjih resnih neželenih učinkov:
Efficib should not be used in patients with type 1 diabetes and must not be used for the treatment of diabetic ketoacidosis. 
Zdravila Efficib se ne sme uporabljati pri bolnikih s sladkorno boleznijo tipa 1 in za zdravljenje diabetične ketoacidoze.
The European Medicines Agency has waived the obligation to submit the results of studies with Efficib in all subsets of the paediatric population in type 2 diabetes mellitus (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je odstopila od zahteve za predložitev rezultatov študij z zdravilom Efficib za vse podskupine pediatrične populacije za sladkorno bolezen tipa 2 (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
Other medicines and Efficib 
Druga zdravila in zdravilo Efficib
During treatment with Efficib, your doctor will check your kidney function at least once a year or more frequently if you are elderly and/or if you have worsening kidney function. 
Med zdravljenjem z zdravilom Efficib bo zdravnik vsaj enkrat letno preveril delovanje ledvic, če pa ste starejša oseba in/ali se vam delovanje ledvic slabša, pa še pogosteje.
No animal studies have been conducted with Efficib. 
Študij na živalih z zdravilom Efficib niso opravili.
What Efficib is and what it is used for What you need to know before you take Efficib How to take Efficib 
Kaj je zdravilo Efficib in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Efficib Kako jemati zdravilo Efficib Možni neželeni učinki
Your doctor will decide when you must stop and when to restart your treatment with Efficib. 
Zdravnik se bo odločil, kdaj morate z jemanjem zdravila Efficib prenehati in kdaj lahko nadaljujete.
Efficib contains two different medicines called sitagliptin and metformin. 
Zdravilo Efficib vsebuje dve različni učinkovini, imenovani sitagliptin in metformin.
You may need more frequent blood glucose and kidney function tests, or your doctor may need to adjust the dosage of Efficib. 
Morda boste morali pogosteje opravljati preiskave glukoze v krvi in delovanja ledvic, zdravnik pa bo morda moral prilagoditi odmerek zdravila Efficib.
Efficib may cause a very rare, but very serious side effect called lactic acidosis, particularly if your kidneys are not working properly. 
Zdravilo Efficib lahko povzroči zelo redek, a zelo resen neželeni učinek, imenovan laktacidoza, zlasti če ledvice ne delujejo pravilno.
If you forget to take Efficib 
Če ste pozabili vzeti zdravilo Efficib
The dose of antihyperglycaemic therapy with Efficib should be individualised on the basis of the patient's current regimen, effectiveness, and tolerability while not exceeding the maximum recommended daily dose of 100 mg sitagliptin. 
Odmerek zdravila Efficib pri antidiabetičnem zdravljenju je treba prilagoditi na podlagi bolnikovega trenutnega režima zdravljenja, učinkovitosti in tolerabilnosti, pri tem pa se ne sme preseči največjega dovoljenega dnevnega odmerka 100 mg sitagliptina.
If you stop taking Efficib 
Če ste prenehali jemati zdravilo Efficib
Pharmacokinetic drug interaction studies with Efficib have not been performed; however, such studies have been conducted with the individual active substances, sitagliptin and metformin. 
Študije farmakokinetičnih interakcij z zdravilom Efficib niso bile izvedene, vendar pa so take študije opravili s posameznima učinkovinama, sitagliptinom in metforminom.
Efficib may cause a very rare (may affect up to 1 in 10,000 people), but very serious side effect called lactic acidosis (see section “Warnings and precautions”). 
Zdravilo Efficib lahko povzroči zelo redek (pojavi se lahko pri največ 1 od 10.000 bolnikov), a zelo resen neželeni učinek, imenovan laktacidoza (glejte poglavje "Opozorila in previdnostni ukrepi").
If you need to have an injection of a contrast medium that contains iodine into your bloodstream, for example, in the context of an X-ray or scan, you must stop taking Efficib before or at the time of the injection. 
Če vam bodo v krvni obtok injicirali kontrastno sredstvo, ki vsebuje jod, na primer zaradi rentgenskega ali drugega slikanja, morate pred časom injiciranja ali v tem času prenehati z jemanjem zdravila Efficib.
Avoid excessive alcohol intake while taking Efficib since this may increase the risk of lactic acidosis (see section “Warnings and precautions”). 
Med jemanjem zdravila Efficib ne uživajte čezmernih količin alkohola, saj lahko to poveča tveganje za laktacidozo (glejte poglavje "Opozorila in previdnostni ukrepi").
Stop taking Efficib for a short time if you have a condition that may be associated with dehydration (significant loss of body fluids) such as severe vomiting, diarrhoea, fever, exposure to heat or if you drink less fluid than normal. 
Za kratek čas prenehajte jemati zdravilo Efficib, če imate stanje, ki je lahko povezano z dehidracijo (znatna izguba telesnih tekočin), kot je hudo bruhanje, driska, zvišana telesna temperatura, izpostavljenost vročini ali če pijete manj tekočine, kot običajno.
If you need to have major surgery you must stop taking Efficib during and for some time after the procedure. 
Če morate na večji kirurški poseg, morate v času posega in še nekaj časa po tem prenehati z jemanjem zdravila Efficib.
If this happens, you must stop taking Efficib and contact a doctor or the nearest hospital immediately, as lactic acidosis may lead to coma. 
V tem primeru morate prenehati jemati zdravilo Efficib in se takoj obrniti na zdravnika ali najbližjo bolnišnico, saj lahko laktacidoza vodi v komo.
The following statements reflect the pharmacokinetic properties of the individual active substances of Efficib. 
V nadaljevanju so naštete farmakokinetične lastnosti posameznih učinkovin v zdravilu Efficib.
Efficib should be given twice daily with meals to reduce the gastrointestinal adverse reactions associated with metformin. 
Zdravilo Efficib je treba jemati dvakrat na dan s hrano, da se zmanjšajo neželeni učinki metformina na prebavila.
What Efficib looks like and contents of the pack 
Izgled zdravila Efficib in vsebina pakiranja
Change in clinical status of patients with previously controlled type 2 diabetes A patient with type 2 diabetes previously well controlled on Efficib who develops laboratory abnormalities or clinical illness (especially vague and poorly defined illness) should be evaluated promptly for evidence of ketoacidosis or lactic acidosis. 
Spremembe kliničnega statusa pri bolnikih s predhodno nadzorovano sladkorno boleznijo tipa 2 Pri bolnikih s sladkorno boleznijo tipa 2, predhodno dobro nadzorovano z jemanjem zdravila Efficib, pri katerih se pojavijo nenormalni izvidi laboratorijskih preiskav ali klinične bolezni (zlasti nejasne ali slabo opredeljene bolezni), je treba čim prej ugotoviti, če imajo ketoacidozo ali laktacidozo.
Efficib with alcohol 
Zdravilo Efficib skupaj z alkoholom
Stop taking Efficib and contact a doctor or the nearest hospital immediately if you experience some of the symptoms of lactic acidosis, as this condition may lead to coma. 
Takoj prenehajte jemati zdravilo Efficib in se obrnite na zdravnika ali najbližjo bolnišnico, če se pojavijo nekateri od simptomov laktacidoze, saj lahko to stanje vodi v komo.
If you take more than the prescribed dosage of this medicine, contact your doctor immediately. 
Če ste vzeli večji odmerek zdravila Efficib, kot bi smeli Če ste vzeli večji odmerek tega zdravila od predpisanega, se takoj posvetujte z zdravnikom.
Efficib is contraindicated in patients with GFR < 30 mL/min and should be temporarily discontinued during conditions with the potential to alter renal function (see section 4.3). 
Zdravilo Efficib je kontraindicirano pri bolnikih z GFR < 30 ml/min in ga je treba začasno ukiniti, če se pojavijo stanja, ki spremenijo delovanje ledvic (glejte poglavje 4.3).
Hepatic impairment Efficib must not be used in patients with hepatic impairment (see section 5.2). 
Jetrna okvara Zdravila Efficib se pri bolnikih z okvaro jeter ne sme uporabljati (glejte poglavje 5.2).
For patients switching from co-administration of sitagliptin and metformin For patients switching from co-administration of sitagliptin and metformin, Efficib should be initiated at the dose of sitagliptin and metformin already being taken. 
Pri bolnikih, ki prehajajo s sočasnega jemanja sitagliptina in metformina Pri bolnikih, ki prehajajo s sočasnega jemanja sitagliptina in metformina, je treba zdravljenje z zdravilom Efficib začeti z odmerkom sitagliptina in metformina, ki ga že jemljejo.
A bioequivalence study in healthy subjects demonstrated that the Efficib (sitagliptin/metformin hydrochloride) combination tablets are bioequivalent to co-administration of sitagliptin phosphate and metformin hydrochloride as individual tablets. 
V bioekvivalenčni študiji pri zdravih osebah so pokazali, da so kombinirane tablete Efficib (sitagliptin/metforminijev klorid) bioekvivalentne sočasni uporabi sitagliptinijevega fosfata in metforminijevega klorida v obliki posameznih tablet.
As metformin and sitagliptin are excreted by the kidney, Efficib should be used with caution as age increases. 
Metformin in sitagliptin se izločata skozi ledvice, zato je pri uporabi zdravila Efficib pri starejših potrebna previdnost.
If you are not sure if any of the above apply to you, talk to your doctor or pharmacist before taking Efficib. 
Če niste prepričani, če kar koli od navedenega velja za vas, se pred začetkom jemanja zdravila Efficib, posvetujte z zdravnikom ali farmacevtom.
Efficib must therefore not be used in women who are breast-feeding (see section 4.3). 
Zato ženske, ki dojijo, zdravila Efficib ne smejo jemati (glejte poglavje 4.3).
Efficib should not be used during pregnancy. 
Bolnice med nosečnostjo ne smejo jemati zdravila Efficib.
When Efficib is used in combination with insulin, a lower dose of insulin may be required to reduce the risk of hypoglycaemia (see section 4.4). 
Kadar se zdravilo Efficib uporablja v kombinaciji z insulinom, bo morda potreben manjši odmerek insulina za zmanjšanje tveganja za hipoglikemijo (glejte poglavje 4.4).
When Efficib is used in combination with a sulphonylurea, a lower dose of the sulphonylurea may be required to reduce the risk of hypoglycaemia (see section 4.4). 
Kadar se zdravilo Efficib uporablja v kombinaciji s sulfonilsečnino, bo morda potreben manjši odmerek sulfonilsečnine za zmanjšanje tveganja za hipoglikemijo (glejte poglavje 4.4).
Patients receiving Efficib in combination with a sulphonylurea or with insulin may be at risk for hypoglycaemia. 
Pri bolnikih, ki prejemajo zdravilo Efficib v kombinaciji s sulfonilsečnino ali z insulinom, se lahko pojavi tveganje za hipoglikemijo.
Efficib has no or negligible influence on the ability to drive and use machines. 
Zdravilo Efficib nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
If a hypersensitivity reaction is suspected, Efficib should be discontinued, other potential causes of the event should be assessed, and alternative treatment for diabetes should be instituted (see section 4.8). 
Pri sumu na preobčutljivostne reakcije morate zdravljenje z zdravilom Efficib prekiniti, oceniti druge morebitne vzroke za ta neželeni učinek in začeti zdraviti sladkorno bolezen z drugimi zdravili (glejte poglavje 4.8).
There have been no therapeutic clinical trials conducted with Efficib tablets however bioequivalence of Efficib with co-administered sitagliptin and metformin has been demonstrated (see section 5.2). 
Kliničnih terapevtskih preskušanj z zdravilom Efficib niso izvedli, vendar pa so dokazali bioekvivalenco zdravila Efficib in sočasne uporabe sitagliptina in metformina (glejte poglavje 5.2).
You will need to stop taking Efficib at the time of the X-ray and for 2 or more days after as directed by your doctor, 
Zdravilo Efficib morate prenehati jemati na dan rentgenskega pregleda in ga ne smete jemati še 2 ali več dni po njem, kot vam je naročil zdravnik, odvisno od delovanja vaših ledvic.
Efficib is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. 
Zdravilo Efficib je indicirano kot dodatek dieti in telesni aktivnosti za izboljšanje urejenosti glikemije pri bolnikih z neustrezno nadzorovano sladkorno boleznijo pri jemanju največjega odmerka samega metformina, ki ga prenašajo, ali pri bolnikih, ki že prejemajo kombinacijo sitagliptina in metformina.
Efficib must be discontinued prior to or at the time of the imaging procedure and not restarted until at least 48 hours after, provided that renal function has been re-evaluated and found to be stable (see sections 4.3 and 4.4). 
Zdravilo Efficib je treba pred slikanjem ali v času slikanja ukiniti in se ga sme ponovno uvesti najmanj 48 ur pozneje, če je bilo delovanje ledvic ponovno ovrednoteno in ocenjeno kot stabilno (glejte poglavji 4.3 in 4.4).
How to take Efficib 
Kako jemati zdravilo Efficib
Cases of inflammation of the pancreas (pancreatitis) have been reported in patients receiving Efficib (see section 4). 
Pri bolnikih, ki so prejemali zdravilo Efficib, so poročali o primerih vnetja trebušne slinavke (pankreatitisa) (glejte poglavje 4).
What Efficib contains 
Kaj vsebuje zdravilo Efficib
For the different doses on metformin, Efficib is available in strengths of 50 mg sitagliptin and 850 mg metformin hydrochloride or 1,000 mg metformin hydrochloride. 
Za različne odmerke metformina je zdravilo Efficib na voljo v jakostih po 50 mg sitagliptina in 850 mg metforminijevega klorida ali 1.000 mg metforminijevega klorida.
The level of digoxin in your blood may need to be checked if taking with Efficib. 
Med sočasnim jemanjem z zdravilom Efficib vam bodo morda morali preveriti vrednosti digoksina v krvi.
Efficib is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (PPAR) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPAR agonist. 
Zdravilo Efficib je indicirano za trojno kombinirano zdravljenje z agonistom receptorja gama, aktiviranega s peroksisomskim proliferatorjem (PPAR - peroxisome proliferator-activated receptor gamma) (tj. s tiazolidindionom) kot dodatek dieti in telesni aktivnosti pri bolnikih z neustrezno nadzorovano sladkorno boleznijo pri jemanju največjega odmerka metformina, ki ga prenašajo, in agonista PPAR.
Efficib is also indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control. 
Zdravilo Efficib je indicirano tudi kot dodatno zdravljenje k insulinu (tj. trojno kombinirano zdravljenje) kot dodatek dieti in telesni aktivnosti za izboljšanje urejenosti glikemije pri bolnikih, pri katerih s stabilnim odmerkom insulina in samim metforminom urejenost glikemije ni zadostna.
If you are not sure, talk to your doctor, pharmacist or nurse before taking Efficib. 
Če niste prepričani, se pred začetkom jemanja zdravila Efficib, posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
Do not take Efficib if any of the above apply to you and talk with your doctor about other ways of managing your diabetes. 
Zdravila Efficib ne jemljite in se z zdravnikom posvetujte o drugih možnostih za nadzor sladkorne bolezni, če kar koli od navedenega velja za vas.